Hussman Strategic Advisors Inc. Acquires Shares of 189,000 Organon & Co. (NYSE:OGN)

Hussman Strategic Advisors Inc. acquired a new stake in shares of Organon & Co. (NYSE:OGN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 189,000 shares of the company’s stock, valued at approximately $2,820,000. Organon & Co. comprises 0.8% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 27th largest position.

Other institutional investors have also modified their holdings of the company. Barclays PLC raised its stake in shares of Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after buying an additional 84,136 shares during the last quarter. Weiss Asset Management LP purchased a new position in shares of Organon & Co. in the 3rd quarter valued at about $32,966,000. Cerity Partners LLC increased its stake in shares of Organon & Co. by 94.0% in the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock valued at $12,766,000 after purchasing an additional 323,308 shares in the last quarter. Foundry Partners LLC purchased a new position in shares of Organon & Co. in the 3rd quarter valued at about $7,642,000. Finally, Beddow Capital Management Inc. increased its stake in shares of Organon & Co. by 38.8% in the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after purchasing an additional 85,775 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on OGN. TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. Finally, Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Trading Down 1.1 %

Shares of Organon & Co. stock opened at $15.32 on Thursday. The stock has a market cap of $3.94 billion, a P/E ratio of 4.60, a P/E/G ratio of 0.86 and a beta of 0.76. The stock’s 50 day simple moving average is $15.35 and its 200-day simple moving average is $17.32. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Analysts predict that Organon & Co. will post 3.78 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.31%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.